Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tom Van den Mooter

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Expert Opinion on Drug Metabolism & Toxicology|August 22, 2015
Management of pulmonary toxicity associated with targeted anticancer therapiesLaure-Anne Teuwen, Tom Van den Mooter, Luc Dirix
Expert Opinion on Biological Therapy|April 14, 2015
Trastuzumab emtansine in advanced human epidermal growth factor receptor 2-positive breast cancerTom Van den Mooter, Laure-Anne Teuwen, Annemie Rutten, et al.
European Journal of Obstetrics, Gynecology, and Reproductive Biology|December 16, 2017
Subcutaneous trastuzumab (Herceptin) versus intravenous trastuzumab for the treatment of patients with HER2-positive breast cancer: A time, motion and cost assessment study in a lean operating day care oncology unitWiebren A A Tjalma, Tom Van den Mooter, Tim Mertens, et al.
Case Reports in Oncological Medicine|February 5, 2024
Beta-HCG Secretion by a Pulmonary Choriocarcinoma in a Male PatientBrecht Devos, Cedric Willemse, Mira Sterckx, et al.
Future Oncology (London, England)|May 2, 2020
Phase II open-label study investigating apalutamide in patients with biochemical progression after radical prostatectomyPiet Dirix, Michiel Strijbos, Tom Van den Mooter, et al.
Nature Communications|November 3, 2023
Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trialLaurence Buisseret, Delphine Loirat, Philippe Aftimos, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Expert Opinion on Drug Metabolism & Toxicology|August 22, 2015
Management of pulmonary toxicity associated with targeted anticancer therapiesLaure-Anne Teuwen, Tom Van den Mooter, Luc Dirix
Expert Opinion on Biological Therapy|April 14, 2015
Trastuzumab emtansine in advanced human epidermal growth factor receptor 2-positive breast cancerTom Van den Mooter, Laure-Anne Teuwen, Annemie Rutten, et al.
European Journal of Obstetrics, Gynecology, and Reproductive Biology|December 16, 2017
Subcutaneous trastuzumab (Herceptin) versus intravenous trastuzumab for the treatment of patients with HER2-positive breast cancer: A time, motion and cost assessment study in a lean operating day care oncology unitWiebren A A Tjalma, Tom Van den Mooter, Tim Mertens, et al.
Case Reports in Oncological Medicine|February 5, 2024
Beta-HCG Secretion by a Pulmonary Choriocarcinoma in a Male PatientBrecht Devos, Cedric Willemse, Mira Sterckx, et al.
Future Oncology (London, England)|May 2, 2020
Phase II open-label study investigating apalutamide in patients with biochemical progression after radical prostatectomyPiet Dirix, Michiel Strijbos, Tom Van den Mooter, et al.
Nature Communications|November 3, 2023
Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trialLaurence Buisseret, Delphine Loirat, Philippe Aftimos, et al.
Pageof 1